orotirelin profile

Orotirelin is a synthetic analogue of the naturally occurring peptide hormone growth hormone-releasing hormone (GHRH). It is a potent and selective GHRH receptor agonist, meaning it binds to and activates the GHRH receptor, leading to the release of growth hormone from the pituitary gland. Orotirelin has been investigated for its potential therapeutic uses in various conditions, including growth hormone deficiency, osteoporosis, and muscle wasting. The synthesis of orotirelin involves chemical modifications of the amino acid sequence of GHRH to enhance its stability and potency. Research on orotirelin has focused on understanding its pharmacological effects, pharmacokinetics, and potential clinical applications. Its importance lies in its ability to stimulate growth hormone production, which can have beneficial effects on growth, bone health, and muscle function.'

orotirelin: increases dopamine release from rat brain [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	68815
CHEMBL ID	2105278
SCHEMBL ID	499207
MeSH ID	M0110990

Synonym
cg-3509
orotirelin
orotireline [french]
l-prolinamide, n-((1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)carbonyl)-l-histidyl-
orotirelinum [latin]
brn 0730085
orotirelina [spanish]
orotirelin [inn]
n-((1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinyl)carbonyl)-l-histidyl-l-prolinamide
62305-86-6
n-[(2s)-1-[(2s)-2-carbamoylpyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]-2,4-dioxo-1h-pyrimidine-6-carboxamide
cg3509
CHEMBL2105278
unii-256m4t7yxy
orotirelinum
orotireline
orotirelina
256m4t7yxy ,
SCHEMBL499207
orotyl-histidyl-proline amide
n-((s)-1-((s)-2-carbamoylpyrrolidin-1-yl)-3-(1h-imidazol-4-yl)-1-oxopropan-2-yl)-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxamide
DTXSID00977864
2,6-dihydroxy-n-[1-{2-[hydroxy(imino)methyl]pyrrolidin-1-yl}-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]pyrimidine-4-carboximidic acid
Q27253925
AKOS040753391

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	22 (100.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	22 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
3,4-dihydroxyphenylacetic acid 3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.. (3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.. dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.	1.96	1	catechols; dihydroxyphenylacetic acid	human metabolite
histamine [no description available]	1.97	1	aralkylamino compound; imidazoles	human metabolite; mouse metabolite; neurotransmitter
hydroxyindoleacetic acid (5-hydroxyindol-3-yl)acetic acid : A member of the class of indole-3-acetic acids that is indole-3-acetic acid substituted by a hydroxy group at C-5.	2.37	2	indole-3-acetic acids	drug metabolite; human metabolite; mouse metabolite
amitriptyline Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.. amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.	1.96	1	carbotricyclic compound; tertiary amine	adrenergic uptake inhibitor; antidepressant; environmental contaminant; tropomyosin-related kinase B receptor agonist; xenobiotic
clonidine Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.. clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.	1.97	1	clonidine; imidazoline
pentobarbital Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236). pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.	3.06	5	barbiturates	GABAA receptor agonist
prazosin Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.. prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.	1.97	1	aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
ritanserin Ritanserin: A selective and potent serotonin-2 antagonist that is effective in the treatment of a variety of syndromes related to anxiety and depression. The drug also improves the subjective quality of sleep and decreases portal pressure.. ritanserin : A thiazolopyrimidine that is 5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one which is substituted at position 7 by a methyl group and at position 6 by a 2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl group. A potent and long-acting seratonin (5-hydroxytryptamine, 5-HT) antagonist of the subtype 5-HT2 (Ki = 0.39 nM), it is used in the treatment of a variety of disorders including anxiety, depression and schizophrenia. It has little sedative action.	1.97	1	organofluorine compound; piperidines; thiazolopyrimidine	antidepressant; antipsychotic agent; anxiolytic drug; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist
apomorphine Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.	1.97	1	aporphine alkaloid	alpha-adrenergic drug; antidyskinesia agent; antiparkinson drug; dopamine agonist; emetic; serotonergic drug
pyrrolidonecarboxylic acid Pyrrolidonecarboxylic Acid: A cyclized derivative of L-GLUTAMIC ACID. Elevated blood levels may be associated with problems of GLUTAMINE or GLUTATHIONE metabolism.. 5-oxo-L-proline : An optically active form of 5-oxoproline having L-configuration.	3.57	9	5-oxoproline; L-proline derivative; non-proteinogenic L-alpha-amino acid	algal metabolite
thiazolidines Thiazolidines: Reduced (protonated) form of THIAZOLES. They can be oxidized to THIAZOLIDINEDIONES.	2.37	2	thiazolidine
5,7-dihydroxytryptamine 5,7-Dihydroxytryptamine: Tryptamine substituted with two hydroxyl groups in positions 5 and 7. It is a neurotoxic serotonin analog that destroys serotonergic neurons preferentially and is used in neuropharmacology as a tool.	2.38	2
substance p [no description available]	1.97	1	peptide	neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent
posatirelin posatirelin: stimulates oxygen consumption	1.97	1	oligopeptide
l-pyroglutamyl-l-histidyl-3,3-dimethylprolinamide [no description available]	3.57	9
proctolin proctolin: neurotransmitter in arthropods or invertebrates	1.97	1
pyro(l-alpha-aminoadipyl)-l-histidyl-l-thiazolidine-4-carboxamide pyro(l-alpha-aminoadipyl)-L-histidyl-L-thiazolidine-4-carboxamide: RN given refers to cpd without isomeric designation	2.37	2
montirelin montirelin: structure given in first source	2.37	2	oligopeptide
piperidines Piperidines: A family of hexahydropyridines.	1.97	1
ascorbic acid Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.	1.96	1	ascorbic acid; vitamin C	coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent

Condition	Relationship Strength	Studies
Anesthesia A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.	2.37	2
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	2.37	2
ALS - Amyotrophic Lateral Sclerosis [description not available]	1.97	1
Amyotrophic Lateral Sclerosis A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)	1.97	1
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	1.97	1
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	1.97	1
Anterior Circulation Transient Ischemic Attack [description not available]	1.97	1
Ischemic Attack, Transient Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)	1.97	1
Injuries, Spinal Cord [description not available]	1.96	1
Spinal Cord Injuries Penetrating and non-penetrating injuries to the spinal cord resulting from traumatic external forces (e.g., WOUNDS, GUNSHOT; WHIPLASH INJURIES; etc.).	1.96	1

orotirelin

Description

Cross-References

Synonyms (25)

Research

Studies (22)

Market Indicators

Research Demand Index: 38.06

Study Types